Liver function tests and low-dose estrogen oral contraceptives

Dickerson, Janet; Bressler, Rubin; Christian, Charles L.

doi:10.1016/0010-7824(80)90086-4

Cited by 13 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results demonstrated no major alterations in the level of CK-MB among all groups studied. These results is similar with pervious study that illustrated there were no differences in CK-MB in women used oral contraceptive during percutaneous coronary intervention (29,30) . In conclusions , we have revealed that OCs could deter the lipid profile status and some enzyme related to the cardiovascular system.…”

Section: Discussionsupporting

confidence: 92%

Evaluation the Relationship between Oral Contraceptives Containing Drospirenone with Dyslipidemia and Risk of Cardiovascular Diseases among Women in Al-kut City

2020

IJFMT

View full text Add to dashboard Cite

Chronic and prolong use of oral contraceptives (OCs) may lead to appearance of undesirable effects in women who used these drugs. There are many types of contraceptives, some contain estrogen and the other contain progesterone, or combination of them in the same drug. This work was performed in a population of adult females to study the relationship between the chronic use of OCs with dyslipidemia and the threat of cardiac diseases. A total 163 volunteers were participated in this study, and, their aged between 21-42 years old. In addition, all women were free of heart disease, dyslipidemia and any hormonal disturbance according to their health records. They were categorized into three differnt groups, the control group included 52 unmarried women and does not use any OCs, group A: included 57 women took OCs (combination pill estrogen and progestin) for less than 6 months, and group B contained 54 women used OCs for more than one year. We meassued lipid profile, and blood indices of cardiovascular disease, like Creatine Kinase-MB (CK-MB), insulin, Lactate Dehydrogenase (LDH) albumin, leptin and HbA1c test. In addition, we determined the coronary risk index, atherogenic Coefficient, and an atherogenic index . Our results recorded a significant increase in total cholesterol, LDL, coronary risk index (TC/HDL), LDH and HbA1c in group2 compared to compared to control group. Furthermore, our data demonstrated no clear differences in Triglyceride, leptin hormone, TG, HDL, insulin, albumin and CK-MB in group2 compared to control. Moreover, the data indicated a significant elevation in the concentration of leptin hormone, LDH, HbA1c, TC, TG, LDL, coronary risk index , atherogenic Coefficient and Atherogenic index, and significant decline in HDL and albumin in group B compared with control group. Therefore, we concluded that oral contraceptive could deter the lipid profile status and some enzyme related to the cardiovascular system. These alterations convey a possible risk for the development of cardiac diseases. Routine screeing of lipid tests would be measured in women used OCs for long periods to avoid any potential risk of cardiac diseases.

show abstract

Section: Discussionsupporting

confidence: 92%

Evaluation the Relationship between Oral Contraceptives Containing Drospirenone with Dyslipidemia and Risk of Cardiovascular Diseases among Women in Al-kut City

2020

IJFMT

View full text Add to dashboard Cite

show abstract

“…In this study, serum total bilirubin levels are higher in OCP users in comparison to non-OCP users. This observation coincides with Osifo 13 , KATZ 14 , Dickerson, et al 15 , Rahim et al 16 , and Heikel and Lathe 17 . Larsson Cohn et al 18 observed that serum bilirubin level was within the standard limit after taking OCP.…”

Section: Discussionsupporting

confidence: 85%

“…21 However, many researchers found increased Alkaline phosphatase levels in OCP users. These results are compatible with Ekhator 20 , KATZ, et al 13 , Hargreaves 23 , Dickerson, et al 15 , and Larsson-Cohn et al 17 . The increased ALP level could be described by cellular degeneration of myocardial, neuronal, and liver cells.…”

Section: Discussionsupporting

confidence: 84%

Effect of Combined Oral Contraceptive Pill on Serum Bilirubin and Alkaline Phosphatase

Rupa

Begum

Jolly

et al. 2023

TAJ: J of Teachers Assoc

View full text Add to dashboard Cite

Background: Combined oral contraceptive is the most known and popular method of contraception. The combined oral contraceptive pill was the first oral contraceptive method and was commercially marketed in 1960. Earlier investigators reported that early oral contraceptive pills had many side effects. Despite the modifications on early OCPs in terms of content and dosage to lessen their side effects, newer contraceptives still have some hepatotoxic effects. Aim and Objectives: The objective of this study was to investigate the effect of low-dose OCP on S. bilirubin and ALP- one of the most important liver enzymes. Materials and Methods: This cross-sectional analytical study was conducted on 184 healthy women aged 20-45. Among them, 92 women were OCP users, and 92 were nonusers. BMI-matched non-OCP users women were recruited in the study for comparison of S. bilirubin and ALP. A systematic sampling technique was applied to select each respondent. Data collection was commenced after obtaining ethical clearance from the Ethical Committee and informed consent from the respondents. Results: The Results showed a significant decrease in serum Alkaline phosphatase among OCP users (p=0.001), but the ALP level was progressively increased with increased duration of OCP use. Serum bilirubin level was within the normal range, but the levels were slightly higher in OCP users but in. OCP users' serum bilirubin levels did not significantly increase with the duration of OCP use (P > 0.05). In summary, OCP users' women are associated with a decreased level of serum Alkaline phosphatase and a slightly increased level of serum bilirubin. Conclusion: So regular monitoring of S. bilirubin and ALP should be done among OCP users women to avoid many unwanted complications. TAJ 2022; 35: No-2: 133-141

show abstract

“…As the trial was not designed to assess the increased values of ALT and AST, it was not possible to distinguish between an effect of repeated OC treatments and the effect of coadministration of OC and oral semaglutide. However, a link between OC use and increased liver parameters has been proposed [53]. Fig.…”

Section: Discussionmentioning

confidence: 99%

Effect of Oral Semaglutide on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women and Furosemide and Rosuvastatin in Healthy Subjects

Jordy

Albayaty

Breitschaft³

et al. 2021

Clin Pharmacokinet

View full text Add to dashboard Cite

Background The first oral glucagon-like peptide-1 receptor agonist (GLP-1RA) comprises semaglutide co-formulated with the absorption enhancer, sodium N- (8-[2-hydroxybenzoyl] amino) caprylate (SNAC). Oral semaglutide may alter the pharmacokinetics of co-administered drugs via effects of semaglutide or SNAC. Two separate one-sequence crossover trials investigated the effects of oral semaglutide and SNAC on the pharmacokinetics of ethinylestradiol, levonorgestrel, furosemide and rosuvastatin. Methods Healthy, postmenopausal women (n = 25) received once-daily combined ethinylestradiol and levonorgestrel (Trial 1) and healthy male and female subjects (n = 41) received single doses of furosemide and rosuvastatin (Trial 2), either alone, with SNAC alone or with oral semaglutide. Lack of drug-drug interaction was concluded if 90% confidence intervals (CIs) for the ratio of area under the plasma concentration-time curve (AUC) or maximum concentration (C max ), with/without oral semaglutide, were within a pre-specified interval (0.80-1.25). ResultsThe AUC values of ethinylestradiol and levonorgestrel were not affected by oral semaglutide co-administration (estimated ratios [90%

show abstract

Liver function tests and low-dose estrogen oral contraceptives

Cited by 13 publications

References 6 publications

Evaluation the Relationship between Oral Contraceptives Containing Drospirenone with Dyslipidemia and Risk of Cardiovascular Diseases among Women in Al-kut City

Evaluation the Relationship between Oral Contraceptives Containing Drospirenone with Dyslipidemia and Risk of Cardiovascular Diseases among Women in Al-kut City

Effect of Combined Oral Contraceptive Pill on Serum Bilirubin and Alkaline Phosphatase

Effect of Oral Semaglutide on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women and Furosemide and Rosuvastatin in Healthy Subjects

Contact Info

Product

Resources

About